Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

• R. K. Ismail,
• F. M. N. H. Schramel,
• M. van Dartel,
• A. M. G. Pasmooij,
• C. M. Cramer-van der Welle,
• D. L. Hilarius,
• A. de Boer,
• M. W. J. M. Wouters,
• E. M. W. van de Garde

Affiliations

R. K. Ismail

Dutch Institute for Clinical Auditing

F. M. N. H. Schramel

Department of Pulmonary Diseases, St Antonius Hospital

M. van Dartel

Medicines Evaluation Board

A. M. G. Pasmooij

Medicines Evaluation Board

C. M. Cramer-van der Welle

Santeon Hospital Group

D. L. Hilarius

Department of Clinical Pharmacy, Rode Kruis Hospital

A. de Boer

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences

M. W. J. M. Wouters

Dutch Institute for Clinical Auditing

E. M. W. van de Garde

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences